Qlucore: At the vanguard of both oncology research and life science M&A - Emergers
Tämä on kolmannen osapuolen analyysi, eikä välttämättä vastaa Inderesin näkemystä tai arvoja
With a strong trend in oncology and life science R&D in favour of precision medicine, data analysis and AI, Qlucore is uniquely positioned at the forefront with its +200 research customers around the globe. This is also evidenced by the M&A activity we’ve seen internationally in 2023. With Net Cash of 80 MSEK above the current market cap of 75 MSEK, the low point in valuation (SEK 15 in Sept ’22) should be behind them. We maintain our fair value of 34-46 SEK in 12-24 months, leaving plenty of upside from today’s level, with progress on the CE application process, new license deals, and first Diagnostics sales as the primary triggers.